Background: Renal injury is a common perioperative complication. The adoption of renal endpoints, standardised and valid for use in perioperative clinical trials, would enhance the quality of perioperative clinical research. The Standardised Endpoints in Perioperative Medicine (StEP) initiative was established to derive standardised endpoints for use in perioperative clinical trials. Methods: A systematic review was conducted to identify renal endpoints currently reported in perioperative clinical trials. In parallel, an initial list of candidate endpoints was developed based on renal theme group expertise. A multiround Delphi consensus process was used to refine this list and produce a suite of recommended perioperative renal outcome measures. Results: Based on our systematic review, 63 studies were included for analysis. Marked heterogeneity and imprecision of endpoint definitions were observed. Our initial list of candidate endpoints included 10 endpoints for consideration. The response rates for Delphi rounds 1, 2, and 3 were 89% (n¼16), 90% (n¼75), and 100% (n¼6), respectively. A final list of four renal endpoints was identified: acute kidney injury defined by the Kidney Disease: Improving Global Outcomes (KDIGO) consensus criteria, acute kidney disease defined by !30% decline in estimated glomerular filtration rate from baseline at 30 days after operation in patients meeting the acute-kidney-injury criteria within 7 days of surgery, the composite of death or renal replacement therapy, and the Major Adverse Kidney Events (MAKE) composite. Conclusions: We identified four key renal outcome measures that should be considered for use in perioperative clinical trials. Using standardised definitions to capture and report these endpoints will facilitate improved benchmarking and meta-analysis of future trials.
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Editor's key points
The Standardised Endpoints in Perioperative Medicine (StEP) initiative was established to derive standardised endpoints for use in perioperative clinical trials. After a systematic review and Delphi consensus process, four key renal outcome measures were identified that should be considered in designing perioperative clinical trials. The use and reporting of these endpoints will support improved benchmarking and metaanalysis of future perioperative trials involving renal outcomes.
Renal injury is a common complication after surgery. One common manifestation of perioperative renal injury, acute kidney injury (AKI), is reported to occur with an incidence of 20e30% in patients undergoing cardiac surgery 1, 2 and from 6%
to as much as 39% in selected cohorts of patients undergoing major non-cardiac surgery. 3e6 The heterogeneity of perioperative renal endpoints and their definitions limit the ability to compare and interpret outcome differences between studies, and to pool results from multiple studies for meta-analysis. The need for endpoints that are consistently defined, valid for the perioperative context and of importance to patients, is increasingly recognised 7e10 and highlights an urgent need for the adoption of standardised renal endpoints valid for use in perioperative clinical trials. In 2015, the European Society of AnaesthesiologyeEuropean Society of Intensive Care Medicine joint taskforce on perioperative outcome measures made a broad recommendation to adopt AKI, defined by the existing Kidney Disease: Improving Global Outcomes (KDIGO) consensus criteria, 11 as a sole perioperative renal outcome. 8 However, neither potential limitations to this definition in the perioperative period nor other potential perioperative renal endpoints were explicitly considered in that report. Whilst the value of 'hard' clinically important endpoints, such as mortality or renal replacement therapy (RRT), is well reasoned, especially in studies intended to provide definitive clinical answers, a typically low perioperative incidence of these outcomes, and issues of competing risk and limited follow-up after hospital discharge, highlights some of the challenges in identifying optimal perioperative renal endpoints. 12 Alternate endpoints, such as Major Adverse Kidney Events (MAKE), a composite that includes outcomes at 30 days after operation and beyond, have recently been advanced for use in clinical trials, 13 but their use within the perioperative context has not yet been extensively evaluated. The overarching aim of the Standardised Endpoints in Perioperative Medicine (StEP) initiative is to derive a set of endpoints suited for use in perioperative medicine trials based on current evidence, expert guidance, and international consensus. 7 Consensus in the definition, timing, and use of perioperative renal endpoints will enhance the interpretation of perioperative clinical research and improve the validity of meta-analyses from pooled results across different trials. We previously published the rationale, goals, and methodologic overview for the development of standardised perioperative renal endpoints under the StEP umbrella. 12 Here, we describe the results of a systematic review and Delphi process to identify and recommend clearly defined renal outcomes for use in perioperative clinical trials.
Methods
We undertook a qualitative systematic review seeking to identify and characterise endpoints currently used to measure perioperative renal injury and function in the anaesthetic, surgical, medical, critical care, cardiovascular, and nephrology literature, and to identify existing guidelines and recommendations for how best to measure renal injury and function in the perioperative period. Our initial remit was to develop a long list of candidate endpoints via a literature search that would include randomised trials, systematic reviews, metaanalyses, published guidelines, consensus statements, and recommendations for the measurement of perioperative renal outcomes, with subsequent refinement through a Delphi process to produce renal endpoint recommendations for use in perioperative trials. However, for several reasons, the theme group elected to modify this strategy (September 12, 2016) during the literature review process. First, a preliminary review of retrieved literature suggested marked heterogeneity in reported endpoints together with heterogeneity and imprecision in endpoint definition. Additionally, despite a prespecified intent to limit the included randomised trials to only those with more than 100 participants and published during or after 2004 in high-impact journals, this aim was countered by systematic reviews and meta-analyses, including small trials, published before the establishment of risk, injury, failure, loss of kidney function, and end-stage kidney disease (RIFLE) AKI terminology, that were likely of limited relevance to current perioperative trial design and clinical practice. Together with the acknowledged need to consider evolving renal endpoints not yet present in the published trial literature, it was therefore agreed that our initial list of candidate renal endpoints for consideration and subsequent refinement should be based on expert opinion of theme group members and their knowledge of existing and evolving literature. It was also agreed to limit our systematic review to randomised trials only, conducted in parallel with the structured endpoint development process, with the expectation that it would objectively characterise some of the limitations to renal endpoints within the existing perioperative randomised trial literature.
For the systematic review, we specified the perioperative period as the pre-, intra-, and postoperative phases, ranging from preoperative evaluation and planning through all durations of reported follow-up, and the perioperative population as all patients undergoing any surgical procedure assessed during any phase of the perioperative period. We defined a renal injury measure as any biochemical or clinical measure of any of kidney injury, abnormal or reduced kidney function relative to baseline, renal insufficiency, recovery of renal function, or initiation of RRT.
Literature search
A systematic search of MEDLINE was conducted (June 16, 2016) to identify randomised trials reporting measures of renal outcome in perioperative trials published during or after 2004, in order to reduce the risk of retrieving outdated or obsolete measures used before the first publication of the consensus diagnostic criteria for AKI (Supplementary Table S1 ). Search terms and strategy were developed and executed by one author (D.R.M.) with the assistance of a medical librarian. Two authors (K.K. and J.R.P.) screened the initially retrieved studies at the title or abstract level, without duplication. The remaining studies were then reviewed in duplicate, at abstract or full manuscript level, as judged appropriate to confirm eligibility (D.R.M. and J.R.P.) with a sustained disagreement resolved by a third reviewer (R.B.). Theme group members were invited to add additional perioperative studies describing potentially important renal endpoints not identified by the initial search for further evaluation. Qualitative extraction of the relevant data was then conducted by a single reviewer (D.R.M.) using a standardised data extraction form with extracted data reviewed by, and agreement sought from, a second reviewer (J.R.P. and F.T.B.). Extracted data were then summarised by a single reviewer (D.R.M.). No specific attempt was made to contact the study authors for endpoint clarification.
The population of interest was adults (!18 yr) undergoing any type of surgery. Exclusion criteria included any trial including patients <18 yr; any trial where a surgical incision was not performed (e.g. endoscopic procedures); any trial where the surgical procedure was renal transplantation, surgery to facilitate RRT, or where a primary characteristic of the study cohort was pre-existing end-stage renal failure or RRT; any trial specifically comparing a surgical intervention with a non-surgical intervention (e.g. percutaneous coronary intervention vs coronary artery bypass grafting); or any trial including fewer than 100 patients. By agreement, studies including patients undergoing transcatheter aortic valve replacement or endovascular aneurysm repair were eligible for inclusion, reflecting the fact that such procedures typically require some form of anaesthesia might progress to open procedures and are associated with a significant incidence of peri-procedural AKI. Given the qualitative nature of the review, secondary (or subgroup) analyses of previously published randomised trials were considered eligible where the secondary analysis focused specifically on renal outcomes. Additionally, to balance the capture of all renal endpoints reported in major perioperative trials whilst simultaneously avoiding the burden associated with the comprehensive examination of large numbers of trials with lesser impact, we restricted our search a priori to journals with higher journal impact factors (IFs). 
Delphi process
A Delphi process was used to integrate input from various medical and other healthcare researchers with experience across anaesthesia and perioperative medicine trials. The StEP Working Group consisted of experienced perioperative triallists and other investigators from various countries, and was overseen by a Steering Committee. A four-stage process similar to that previously described by Myles and colleagues 14 was used to develop and refine recommended perioperative clinical trial endpoints for renal outcomes.
Stage 1: establishing a preliminary list of trial endpoints and their definitions
As described previously, the theme group elected to develop the preliminary long list of candidate endpoints in parallel with the systematic review. Guided by theme group expert opinion, together with existing and evolving literature, this preliminary list of precisely defined endpoints attempted to address some of the imprecision and variability highlighted by the systematic review, and also provided an opportunity to include newer endpoints currently being utilised by large trials (i.e. MAKE) that had not yet been published at the time of the review.
Stage 2: formal rating of the recommendations (Delphi round 1)
A Delphi questionnaire containing the list of candidate endpoints and their definitions was distributed to all members of the StEP renal theme subgroup (n¼6) and StEP Steering Committee (n¼12) (Supplementary Table S2 ). The participants were asked to score each of the items listed using a scale from 1 to 9, with 1e3 labelled 'not that important or invalid', 4e6 labelled 'important but requires revision', and 7e9 labelled 'critical for inclusion'.
Stage 3: Delphi round 2
The second Delphi round was broadened to include all participants from the entire StEP Working Group (n¼83). In preparation, each item from the first Delphi survey, together with the number of respondents and median score, was tabulated and circulated to theme group members for consideration (Supplementary Table S3 ) before a discussion via teleconference (June 23, 2017). After this, a reduced set of items was carried forward to the second Delphi round. Round 2 participants were asked to re-score each item using a second, modified questionnaire (Supplementary Table S4 ). Consensus was prospectively defined by support from at least 70% of participants rating an endpoint as 'critical' (score !7).
Stage 4: developing final recommendations and Delphi round 3
Participants in the third Delphi round were restricted to only those members of the StEP renal theme group (n¼6). As before, summary results of the previous two Delphi rounds were provided to the participants (Supplementary Table S5 ) with an invitation for an e-mail discussion before finalising the presentation of endpoints for the third round of voting (Supplementary  Table S6 ). In the third round of voting, each endpoint was additionally rated for: (i) validity, (ii) reliability, (iii) feasibility, and (iv) patient centredness. Similarly, an assessment of the internal validity of composite endpoints was addressed through respondents scoring the following four questions: (i) are components of the endpoint of similar importance to patients, (ii) do components of the endpoint occur with similar frequency, (iii) are components of the endpoint likely to have similar relative risk reductions, and (iv) is the underlying biology of the components of the endpoint similar?
Each Delphi round was coordinated by the Research Unit of the Department of Anaesthesia and Perioperative Medicine at Alfred Hospital in Melbourne, Australia. A more detailed description of this process is provided in Supplementary Appendix S1.
Results
A total of 415 studies were retrieved from our initial search. After appropriate exclusions and the addition of 10 studies based on the recommendation of theme group members, 63 studies were included in the final analysis (Fig. 1) . Summary results of the qualitative systematic review of existing renal endpoints in perioperative clinical trials from the 63 included studies are presented in Table 1 . Less than half of the included studies used previously published consensus criteria (RIFLE, Acute Kidney Injury Network, KDIGO, and Valve Academic Research Consortium-2)
11,77e79 to define and report AKI. The time frame for the application of these criteria varied widely, ranging from 2 h to 2 yr after operation, and was at times unclear. Similarly, reporting of oliguria, either in isolation or as a component of the consensus criteria to diagnose AKI, was inconsistent and at times unclear. Thirteen studies reported delta S Cr as an endpoint (absolute, proportionate, or both) with Only one study included DS Creatinine as a primary endpoint.
A non-KDIGO threshold change (absolute or %) in S Creatinine Twenty-one studies used an absolute or proportionate threshold increase in S Cr distinct from those used by any of the named consensus criteria for AKI as a perioperative renal endpoint. The time frame for evaluation varied and was at times unspecified; included 1 day, 2 days, 3 days, 4 days, 5 days, 7 days, 30 days, in-hospital, in-ICU, and 1 yr. Of these studies, one reported a threshold increase in S Cr !0.3 mg dl À1 calculated as the difference between maximal postoperative S Cr and preoperative S Cr as an outcome without other reference to consensus criteria. In five studies, this endpoint was a stand-alone primary endpoint including one study, in which the analysis represented a secondary analysis of previously reported trial data. In five studies, this endpoint formed one component of a broad extra-renal composite primary endpoint. Novel/damage biomarkers Eight studies reported renal endpoints based on novel/damage renal biomarkers, including urinary and plasma NGAL, plasma cystatin C, and urinary TIMP-2/IGFBP-7. These studies typically quantified the biomarker as a continuous variable, a deltacontinuous variable, or an area-under-the-curve variable rather than using a prespecified threshold to define injury. One study reporting TIMP-2/IGFBP-7 used a threshold value >0.5, which differs from NephroCheck® manufacturer/FDA recommended thresholds. In one study only was a novel/damage biomarker the primary endpoint. A measured change in GFR (i.e. not based on an estimating equation)
One study reported creatinine clearance as a perioperative endpoint at the end of surgery and again at 48 h after operation. It was not the study primary endpoint.
Renal replacement therapy Thirty-four studies reported RRT as a renal endpoint. The time frame for evaluation varied and was not always explicitly described; included in-ICU, in-hospital, 14 days, 28 days, 30 days, and 1 yr, and one study reporting the use of RRT recorded at 5 yr after operation. Fourteen studies included RRT as a primary endpoint, most commonly as one component of a broad extra-renal composite primary endpoint. Only three studies reported RRT as a stand-alone primary endpoint, and one of these analyses represented a post hoc secondary analysis of data from a previously published trial.
Mortality
Sixty studies reported mortality. The time frame for evaluation varied and not always explicitly described; included 48 h, in-ICU, in-hospital, 14 days, 28 days, 30 days, 90 days, 180 days, 1 yr, and 2 yr, and one study reporting mortality to 8 yr after operation. Mortality was included as a primary endpoint in 24 studies, although typically as one component of a broad extra-renal or cardiovascular composite primary endpoint. MAKE This was not used as a renal endpoint in any of the included studies. Any metric of renal recovery One study reported the proportion of patients in each group that recovered from postoperative AKI, defined as no longer meeting creatinine-based criteria for AKI (last available S Cr before hospital discharge <1.5Âpreoperative S Cr ). It was not the primary endpoint for the study.
the time frame of evaluation varying from 48 h to in-hospital, 30 days, 1 yr, or unspecified. Twenty-one studies reported an absolute of proportionate threshold change in S Cr , inconsistent with the existing consensus criteria, with the time frame for evaluation again varied and not always specified. Thirtyfour studies reported RRT as an endpoint, with 14 including it as either a stand-alone primary endpoint alone or part of a broad extra-renal composite primary endpoint. Mortality was reported in 60 studies. Only one study reported any metric of renal recovery. MAKE was not used as a renal outcome in any of the included studies.
Response rates for the first, second, and third Delphi rounds of voting were 89% (n¼16), 90% (n¼75), and 100% (n¼6), respectively. The final summary results for each of Delphi rounds 1e3 are presented in Table 2 .
After the first round of voting, one of the original 10 candidate endpoints (oliguria) was removed. At the request of theme group members, two items achieving a median score <7 (delta S Cr and novel biomarkers of renal injury) were retained and carried forward to the second Delphi round. Although mortality and RRT were both identified as critically important endpoints when rated individually, they were retained only as a single composite for subsequent voting rounds. This decision was based on the fact that both RRT and mortality are typically uncommon perioperative events. Assuming a baseline incidence of 3% (markedly higher than that reported for either mortality or RRT in several large contemporary perioperative trials, 47,57,80e82 a sample size >10 000 would be required to provide 80% power to detect a 30% reduction in event rate. Combining either death or RRT into a single composite endpoint effectively deals with the issue of competing risk in patients who die without commencing RRT. In total, seven outcomes were carried forward to the second round of Delphi voting. At the conclusion of the second round of voting, delta S Cr and novel biomarkers of renal injury both achieved a median score of 3 and were eliminated. Of the two versions of the KDIGO consensus criteria used to define AKI (i.e. with and without oliguric criteria), only the definition that excluded oliguria was identified as meeting pre-specified criteria for consensus as a critical endpoint for inclusion. However, after discussion within the theme group, it was agreed to carry both definitions forward to the third round of Delphi voting, with a request that participants score these two alternate AKI definitions to reflect clearly their preference for one over the other. Four renal endpoints (including two alternate definitions for AKI) were thus carried forward to the third round of voting, scored only by renal theme group members. In the third round of voting, each of the presented endpoints achieved consensus as critically important for reporting within a perioperative clinical trial context: (1a) AKI: defined by the current KDIGO criteria (creatinine, oliguria, or initiation of RRT criteria) (1b) AKI: defined by the current KDIGO criteria, excluding oliguric criteria (2) Acute kidney disease (AKD) Cr30 : defined by !30% decline in estimated glomerular filtration rate (eGFR) from baseline at 30 days after operation in a patient who previously met creatinine-based KDIGO criteria for AKI within 7 days of surgery (3) Death or RRT: within a clearly defined time interval, preferably 30 or 90 days, after surgery (4) MAKE (mortality or RRT of any duration or !30% decline in eGFR from baseline measured at a pre-specified time, e.g. 30 or 90 days after operation)
The renal theme group evaluation of validity, reliability, feasibility, and patient centredness of each endpoint, together with an assessment of the internal validity of the two included composite endpoints, is presented in Tables 3 and 4 . 
Discussion
We undertook a systematic review and used a Delphi process to achieve consensus on standardised renal endpoints for perioperative clinical trials from a broad range of experts involved in such studies. The group identified four standardised endpoints (including two alternate definitions for AKI) that represent key perioperative renal outcomes; we recommend that each be considered when selecting outcomes for reporting in perioperative trials. Although the first diagnostic consensus criteria for AKI appeared more than a decade ago, 77 our systematic review confirms that AKI remains inconsistently measured and reported in perioperative trials in terms of both time frame of measurement and whether or not urine output criteria are included. Despite the consistent and strong association between AKI and serious adverse outcomes, a short-term change in S Cr remains a biochemical surrogate with a questionable validity as an outcome in trials of potentially nephroprotective interventions, 83 and it is not currently accepted by the US Food and Drug Administration (FDA) as an endpoint for registration trials. 84 Urine output and changes in S Cr might each be sensitive to perioperative patient management strategies, including volume of i.v. fluid administered, poorly defined changes in creatinine metabolism, and an intense neurohumoural response, potentially confounding AKI identification during the perioperative period. However, the strength of epidemiological evidence supporting the validity of AKI as a marker of significant renal injury, together with clear temporal proximity to perioperative interventions and feasibility for collection within a perioperative trial context, supports the continued recommendation of AKI defined by the KDIGO criteria as a standardised renal outcome in perioperative trials. Despite evolving evidence to support the validity and significance of urine output criteria for AKI in a critical care setting, 85 this may not be generalisable to the broader perioperative context where there remains a lack of high-quality evidence to support or refute their validity. In a recent perioperative trial 86 reporting a marked reduction in AKI with study intervention, the effect was largely driven by a reduction in patients meeting oliguric criteria for AKI, highlighting the need to clarify the validity of these criteria in the perioperative setting. Whilst the final round of voting of the theme group indicated a similar level of support for a definition of AKI with or without oliguria, there was an agreement on the need for investigators to clearly articulate whether or not urine output criteria were included in their study definition of AKI, and to report results in a manner that would allow extraction of AKI incidence according to independent creatinine-based, urine-output-based, and combined criteria.
Recognising the limitations associated with AKI as a perioperative trial endpoint, the recommendation for reporting AKD 30 as an outcome, defined by !30% decline in eGFR from baseline at 30 days after operation in a patient previously meeting creatinine-based KDIGO criteria for AKI within 7 days of surgery, was based on data from a large perioperative cohort showing an association between this outcome and subsequent end-stage renal disease and mortality. 84 This intermediate endpoint might effectively operationalise the recent Acute Disease Quality Initiative consensus report on AKD 87 into a pragmatic renal endpoint for perioperative trials, capturing patients with a sustained reduction in renal function at a time (30 days after operation) when renal function would be expected to have stabilised and total body creatinine and fluid Table 3 Round 3 Delphi voting summary results for assessment of validity, reliability, feasibility, and patient centredness of each endpoint. AKI, acute kidney injury; KDIGO, Kidney Disease: Improving Global Outcomes; MAKE, major adverse kidney events; RRT, renal replacement therapy. balance returned to steady state. Although supported by recent observational data, 84 the specific selection of a 30% reduction in eGFR at 30 days after operation represents an arbitrary balance between sensitivity, specificity, and feasibility, and has not been previously reported as a perioperative clinical trial endpoint. Nevertheless, it reflects the increasingly recognised need to look beyond the immediate perioperative period to capture the full significance of perioperative complications. 88 The feasibility of obtaining 30-day S Cr values, however, might limit the widespread applicability of this endpoint outside of well-resourced large trials where postdischarge follow-up is routine. The composite outcome of new RRT or mortality was universally identified as critical by all members of the theme group. It was agreed that this should include the postoperative initiation of any form of RRT regardless of indication or duration, with the exception of RRT used solely during cardiopulmonary bypass in patients undergoing cardiac surgery. We recommend that individual components of the composite outcome be separately reported to enhance the interpretation of results, acknowledging concern that nonrenal causes of death create a potential for this endpoint to misclassify some patients. In addition to reporting commencement of new RRT, it is also recommended that perioperative trials specify both the duration of RRT and whether there has been sustained separation from RRT within a pre-specified time (e.g. 90 days), where possible, as evidence of renal recovery. The nuances of reporting actual provision of RRT vs meeting study-specific criteria for RRT were also discussed, with an agreement to recommend reporting the actual provision of RRT as a more pragmatic definition of the endpoint. Nevertheless, the value of prespecified criteria for initiation of RRT within clinical trial protocols is acknowledged.
Although not reported by any trial identified at the time of our systematic review, the MAKE composite, favoured in principle by the FDA, 10,89 has more recently appeared as an endpoint in several perioperative and other clinical trials. 86,90e92 In contrast to the AKD 30 endpoint, MAKE does not require patients to have first met the criteria for AKI within 7 days of surgery and might therefore capture significant renal injury that was 'subclinical' in the immediate perioperative period. Despite strong support from the theme group for the overall validity and patient-centred nature of this endpoint, there remained some concern over both feasibility and internal validity of the unweighted combination of the three components of MAKE, and it is recommended that each of the component outcomes be clearly and separately reported to facilitate optimal interpretation of study results. Although a 30% decline in eGFR from baseline at 30, 60, or 90 days after surgery remains a biochemical surrogate outcome, observational data from the perioperative setting support such a decline as a reasonable surrogate for risk of future end-stage renal disease and death. 84 However, heterogeneity in the threshold used to define this component of MAKE is already evident amongst the small number of published studies reporting this endpoint. Importantly, this threshold might warrant revision as experience with MAKE increases, and additional data clarifying the link between an intervention's effect on varying thresholds of persistently worsened renal function (defined by eGFR) and its effect on more established (but less frequent and typically more delayed) outcomes of chronic kidney disease (CKD) or end-stage renal disease become available. 89, 93 The writing group recognises the wide diversity of purpose, phase, and context in which perioperative trials are conducted, including marked resource variation, and the current StEP initiative is not intended to dictate idealistic and unrealistic renal endpoints on which every clinical study should be based. Rather, these recommendations provide guidance on endpoints best suited to large trials together with standardised definitions for these endpoints. However, routine capture and reporting of these standardised renal endpoints are strongly encouraged for all studies wherever feasible with the intent that this will enable a more meaningful comparison and pooling of results from such studies in the future. Importantly, and with their limitations acknowledged, alternate primary endpoints might be appropriate for early phase, smaller trials, such as those used to pilot a new intervention, explore mechanistic associations, or test the feasibility of a novel study protocol. The use of 'novel' biomarkers as renal endpoints in perioperative studies was not supported by the broader StEP Working Group. They remain a biochemical and intermediate endpoint with an unclear association with important patient-centred outcomes, such as mortality, need for RRT, and CKD. Moreover, the clinical significance of a difference in biomarker levels occurring as the result of an intervention remains unknown. However, the renal theme group acknowledges the strength of basic science underpinning the potential utility of such markers and their recently demonstrated role in cohort enrichment for a perioperative trial. 86 Their potential role as perioperative trial endpoints may warrant revision in the future as our understanding of renal injury increases. Our process has some important limitations. The decision to restrict our initial literature search to an a priori defined group of high-impact journals will, by definition, have limited our data set of currently used perioperative trial endpoints. Nevertheless, broadened inclusion criteria would likely have further highlighted the heterogeneity and imprecision of existing trial endpoints without impacting the parallel process of endpoint development through our structured Delphi process. With the exception of the composite RRT/mortality endpoint, each of the recommended endpoints includes a creatinine-based component. Further work is required to explore the subjective importance to patients of such intermediate creatinine-based outcomes. The potential for the method of baseline S Cr definition to result in misclassification of endpoints defined by a change in S Cr from baseline has been documented 94 with a subsequent study reporting that mean S Cr calculated from all available values between 7 and 365 days before admission yielded the highest agreement with a nephrologist-adjudicated assessment of baseline. 95 However, the majority of patients within this single-centre study were admitted to a medical service reducing generalisability to the perioperative context. Whilst there are insufficient data currently available to make specific recommendation for defining baseline S Cr in the perioperative trial context, there was a universal agreement amongst the StEP renal theme group that it should be based on one or more clearly defined preoperative values. Our process made no recommendation on endpoints specifically measuring renal recovery, a characteristic of renal injury that may represent an important opportunity for intervention to alter progression to longer-term adverse outcomes. Metrics of renal recovery have typically not been reported in perioperative trials. Although observational work has begun to explore patterns of recovery after AKI, 96 validated endpoints to measure such recovery are not well established.
In conclusion, we identified four key renal outcome measures that should be considered for use by investigators designing perioperative clinical trials. Using standardised definitions to capture and report these endpoints will facilitate uniform data reporting and support improved benchmarking and meta-analysis of future trials. 
